The pharmacoscopy high-content imaging platform was used to analyze changes in viable and non-viable AML cells and CD14+/CD33+ normal cells as a function of CC-96191 or lintuzumab over time without the addition of exogenous effector cells. The gene discussed is CD33; the disease is acute myeloid leukemia.